Holen Sie sich die Stockscreener-App
23.90
1.01%
0.24
Schlusskurs vom Vortag:
$23.66
Offen:
$23.27
24-Stunden-Volumen:
1.61M
Relative Volume:
0.95
Marktkapitalisierung:
$3.00B
Einnahmen:
$415.62M
Nettoeinkommen (Verlust:
$-2.38M
KGV:
-841.55
EPS:
-0.0284
Netto-Cashflow:
$16.92M
1W Leistung:
+0.50%
1M Leistung:
-8.18%
6M Leistung:
-0.91%
1J Leistung:
+47.44%
1-Tages-Spanne:
$23.27
$24.02
1-Wochen-Bereich:
$23.21
$24.45
52-Wochen-Spanne:
$16.21
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Firmenname
Arcutis Biotherapeutics Inc
Sektor
Branche
Telefon
805-418-5006
Adresse
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
23.90 | 3.19B | 415.62M | -2.38M | 16.92M | -0.0284 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Eingeleitet | Goldman | Neutral |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-10-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-09-07 | Eingeleitet | Needham | Buy |
| 2022-03-17 | Eingeleitet | Goldman | Buy |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-05-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Hochstufung | Goldman | Neutral → Buy |
| 2020-10-08 | Eingeleitet | Truist | Buy |
| 2020-02-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Eingeleitet | Cowen | Outperform |
| 2020-02-25 | Eingeleitet | Goldman | Neutral |
| 2020-02-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Arcutis Biotherapeutics CMO Patrick Burnett Sells Shares to Cover Tax Withholding on RSU Vesting - Kalkine Media
Tejara Capital Ltd Buys Shares of 113,084 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Polar Capital Holdings Plc Buys Arcutis Biotherapeutics Inc (ARQ - GuruFocus
Arcutis (NASDAQ: ARQT) director to sell 1,072 shares - Stock Titan
ARQT Looks 18.5% Undervalued on GF Value™ After Health Canada Ap - GuruFocus
PrZORYVE® Cream 0.05% Receives Health Canada Approval for Children Aged 2 to 5 Years with Mild to Moderate Atopic Dermatitis - PR Newswire Canada
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,730 Shares - MarketBeat
Arcutis (NASDAQ: ARQT) officer to sell 1,697 shares after recent August trades - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup - ChartMill
Arcutis (ARQT) Q2 2026 Earnings: EPS Beats Its Estimate in Latest Trading; Shares After the Report: The Stock Ends Up 3.63% at the CloseSegment Revenue Breakdown - Vinanet
Arcutis (NASDAQ: ARQT) holder plans $123,834 August sale - Stock Titan
Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action? - webull.com
Arcutis (ARQT) Q2 2026 Earnings Call Transcript - AOL.com
Arcutis Biotherapeutics (ARQT) Gains 1.39% as Shares Push Toward Key ResistanceSupport Level Bounce - Vinanet
Liquidity Mapping Around (ARQT) Price Events - Stock Traders Daily
Polar Capital discloses 5.28% Arcutis Biotherapeutics (ARQT) ownership in Schedule 13G - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals - ChartMill
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com - Investing.com Australia
Patrick Burnett Sells 6,700 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Patrick Burnett Sells 8,300 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock - Investing.com
Bank of America Corp DE Acquires 547,835 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis insider plans sale of 15,000 shares | ARQT SEC FilingForm 144 - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup - ChartMill
H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $34 - Moomoo
HC Wainwright Analysts Boost Earnings Estimates for ARQT - MarketBeat
ARQT Technical Analysis & Stock Price Forecast - Intellectia AI
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
24 New Arcutis Employees Get Stock Awards That Vest Over Four Years - Stock Titan
State Street Corporation (ARQT) discloses 4.7% beneficial stake in Arcutis - Stock Titan
Analysts Set Expectations for ARQT Q1 Earnings - MarketBeat
Arcutis Biotherapeutics EVP Matsuda sells $32,123 in stock By Investing.com - Investing.com South Africa
Guggenheim raises Arcutis stock price target on strong Zoryve sales By Investing.com - Investing.com South Africa
Arcutis CEO Todd Watanabe sells $114,261 of ARQT stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics EVP Burnett sells $24,941 in stock By Investing.com - Investing.com South Africa
ARQT Maintains Overweight Rating -- Price Target Raised to $38.0 - GuruFocus
Arcutis Biotherapeutics (NASDAQ:ARQT) Given New $40.00 Price Target at Needham & Company LLC - MarketBeat
Arcutis Biotherapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ARQT) 2026-08-06 - Seeking Alpha
Did Profitability, Higher 2026 Guidance, and New Commercial Leadership Just Recast Arcutis Biotherapeutics' (ARQT) Investment Narrative? - simplywall.st
ARQT Maintained by Guggenheim -- Price Target Raised to $38 - GuruFocus
Arcutis Biotherapeutics EVP Matsuda sells $32,123 in stock - Investing.com
Guggenheim raises Arcutis stock price target on strong Zoryve sales - Investing.com
Arcutis Biotherapeutics EVP Burnett sells $24,941 in stock - Investing.com
Form 4 Arcutis Biotherapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
ARQT Maintains Buy Rating by Needham -- Price Target Raised to $40 - GuruFocus
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability - The Motley Fool
Arcutis Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $36.62, Implies 35% Upside - TradingView
Arcutis CEO Todd Watanabe sells $114,261 of ARQT stock - Investing.com
Arcutis Biotherapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Finanzdaten der Arcutis Biotherapeutics Inc-Aktie (ARQT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arcutis Biotherapeutics Inc-Aktie (ARQT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Curran Terrie | Director |
Aug 27 '26 |
Sale |
25.03 |
38,200 |
956,123 |
23,526 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):